Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Kathryn Humphrey, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Ben Byrne, Naseer Qayum, Carmelo Carlo-Stella

Blood (2022) 140 (Supplement 1): 178–180.

https://doi.org/10.1182/blood-2022-157777

Published: 2022

Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Max S. Topp, Monica Tani, Michael Dickinson, Nilanjan Ghosh, Armando Santoro, Antonio Pinto, Francesc Bosch, Christopher P. Fox, Armando López-Guillermo, Claudia Carlucci, Chun Wu, Kathryn Humphrey, Pauline Baumlin, Martin Barrett, Naseer Qayum, Franck Morschhauser

Blood (2022) 140 (Supplement 1): 1775–1777.

https://doi.org/10.1182/blood-2022-157732

Published: 2022

Journal Articles

Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies

Yu-Qin Song, Hui-Lai Zhang, Hui-Qiang Huang, Qing-Yuan Zhang, Hong-Mei Jing, Chao Wang, Chun Wu, Dong-Hang Li, Yu Dai, Kathryn Humphrey, Jun Zhu

Blood (2022) 140 (Supplement 1): 12050–12051.

https://doi.org/10.1182/blood-2022-157544

Published: 2022

Journal Articles

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Blood (2022) 140 (Supplement 1): 1062–1064.

https://doi.org/10.1182/blood-2022-157554

Published: 2022

Journal Articles

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

Michael Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Krish Patel, Cyrus Khan, Nancy L. Bartlett, Gloria Iacoboni, Mark Hertzberg, Sirpa Leppä, Eric Van Den Neste, Monica Tani, Guillaume Cartron, Antonio Salar, David Perez-Callejo, Linda Lundberg, James Relf, Emma Clark, Kathryn Humphrey, Martin Hutchings

Blood (2021) 138 (Supplement 1): 2478.

https://doi.org/10.1182/blood-2021-146845

Published: 2021

Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study

Nilanjan Ghosh, William Townsend, Michael Dickinson, Max Topp, Monica Tani, Armando Santoro, Michael Crump, Franck Morschhauser, Steven Le Gouill, Amitkumar Mehta, Anesh Panchal, Chun Wu, Martin Barrett, Kathryn Humphrey, Naseer Qayum, Martin Hutchings

Blood (2021) 138 (Supplement 1): 2479.

https://doi.org/10.1182/blood-2021-147780

Published: 2021

Journal Articles

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Blood (2021) 138 (Supplement 1): 128.

https://doi.org/10.1182/blood-2021-148778

Published: 2021

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Kathryn Humphrey, David Perez-Callejo, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Emma Clark, Carmelo Carlo-Stella

Blood (2021) 138 (Supplement 1): 130.

https://doi.org/10.1182/blood-2021-148949

Published: 2021

Journal Articles

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Shuo Ma, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W. Roberts

Blood (2021) 138 (10): 836–846.

https://doi.org/10.1182/blood.2020009578

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Blood (2021) 137 (5): 600–609.

https://doi.org/10.1182/blood.2020006578

Published: 2021

Includes: Supplemental data

Journal Articles

Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

Blood (2020) 136 (23): 2628–2637.

https://doi.org/10.1182/blood.2020005588

Published: 2020

Includes: Supplemental data

Journal Articles

Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing

Nassim Djebli, Peter N Morcos, Félix Jaminion, Elena Guerini, Nicole A Kratochwil, Nicole Justies, Eginhard Schick, Antonia Kwan, Kathryn Humphrey, Linda Lundberg, David Carlile

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136311

Published: 2020

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Carmelo Carlo-Stella, MD, Emmanuel Bachy, MD PhD, Fritz C. Offner, MD PhD, Franck Morschhauser, MD PhD, Michael Crump, Gloria Iacoboni, MD, Anna Sureda Balari, MD PhD, Joaquin Martinez-Lopez, MD, Linda Lundberg, Mark Dixon, David Perez Callejo, James Relf, David Carlile, Emily Piccione, Kathryn Humphrey, Michael Dickinson, DMed Sci

Blood (2020) 136 (Supplement 1): 46–48.

https://doi.org/10.1182/blood-2020-136044

Published: 2020

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Danielle M. Brander, MD, John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Shuo Ma, MD PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Michael Y. Choi, MD, Kathryn Humphrey, BSc, Abdullah Al Masud, PhD, Ruby Nandam, RN, MSN, Amanda Jacobson, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3036.

https://doi.org/10.1182/blood-2019-126508

Published: 2019

Journal Articles

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Eugene C Kim, PhD, Jinzhen Fan, PhD, Christopher R Bolen, PhD, Alexandra Bazeos, MD PhD FRCPath, Yanwen Jiang, PhD, Sandhya Balasubramanian, MS, Rama Balakrishnan, PhD, Andrea Knapp, PhD, Kathryn Humphrey, BSc, Tina G Nielsen, MD PhD, Jeffrey M. Venstrom, MD PhD, Genevive Hernandez, PhD, Joseph N Paulson, PhD

Blood (2019) 134 (Supplement_1): 2788.

https://doi.org/10.1182/blood-2019-124687

Published: 2019

Journal Articles

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 355.

https://doi.org/10.1182/blood-2019-123930

Published: 2019

Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Blood (2019) 134 (Supplement_1): 356.

https://doi.org/10.1182/blood-2019-123678

Published: 2019

Journal Articles

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Andrew W. Roberts, Shuo Ma, Thomas J. Kipps, Steven E. Coutre, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, John C. Byrd, Kathryn Humphrey, Lang Zhou, Brenda Chyla, Jacqueline Nielsen, Jalaja Potluri, Su Young Kim, Maria Verdugo, Stephan Stilgenbauer, William G. Wierda, John F. Seymour

Blood (2019) 134 (2): 111–122.

https://doi.org/10.1182/blood.2018882555

Published: 2019

Includes: Supplemental data

Journal Articles

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Blood (2019) 133 (26): 2765–2775.

https://doi.org/10.1182/blood-2019-01-896290

Published: 2019

Includes: Supplemental data

NARROW

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only